Scotiabank Maintains Sector Outperform on Myriad Genetics, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst Sung Ji Nam maintains a Sector Outperform rating on Myriad Genetics (NASDAQ:MYGN) and raises the price target from $29 to $34.
August 13, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scotiabank analyst Sung Ji Nam maintains a Sector Outperform rating on Myriad Genetics and raises the price target from $29 to $34.
The raised price target from $29 to $34 and the maintained Sector Outperform rating by Scotiabank are positive signals for investors, likely leading to a short-term increase in MYGN's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100